24Oct 2022
Cost‐utility analysis of semaglutide for type 2 diabetes after its addition to the National Medical Insurance System in China

Cost‐utility analysis of semaglutide for type 2 diabetes after its addition to the National Medical Insurance System in China

The primary research purpose is to compare the long‐term cost‐effectiveness of semaglutide (SEMA) with dulaglutide (DULA) for patients with inadequately controlled type 2 diabetes throughout their lifetime. In addition, this study also aimed to investigate a further price cut for SEMA to provide sound advice for government drug price adjustments. The study's findings suggested that SEMA is expected to be a cost‐effective choice compared with DULA for patients with type 2 diabetes inadequately controlled from the cost‐utility analysis. However, there is still scope to further reduce the annual cost of SEMA.

  • #endo-diabetology

Like

Save

Share